Immunotherapy for advanced liver cancer
Part of Cancer clinical trials.
This trial tests how well immunotherapy drugs work for people with advanced liver cancer that cannot be treated with surgery. It focuses on patients whose liver is still working fairly well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with advanced liver cancer that has spread or cannot be removed.
- Your doctor plans to treat you with an immunotherapy drug like atezolizumab-bevacizumab or durvalumab-tremelimumab.
- Your liver function is good or moderately good (Child-Pugh score A or B up to 7, or ALBI grade 1 or 2).
- You do not have another active cancer besides liver cancer.
- You do not have an autoimmune disease that needs treatment with steroids or other immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
This trial studies how well immunotherapy drugs (atezolizumab and bevacizumab) work for people with advanced liver cancer that cannot be treated with local procedures. It looks at real-life results to see if these treatments help people live longer and feel better.
This study tests a first-line immunotherapy combination (like atezolizumab + bevacizumab or similar drugs) for advanced liver cancer that can't be removed. It aims to see how well these treatments work and how safe they are in real-world patients.
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
This Phase 1/2 study tests new combinations of immune system medicines in people with advanced liver cancer that cannot be cured by surgery. It looks for safer treatment and signs that the medicines can shrink or control the cancer.
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.